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Extended-spectrum beta-lactamases (ESBLs) were first
reported in 1983 (1), and plasmid-mediated AmpC beta-
lactamases were reported in 1988 (2). Typically, ESBLs are
mutant, plasmid-mediated beta-lactamases derived from
older, broad-spectrum beta-lactamases (e.g., TEM-1, TEM-2,
SHV-1), which have an extended substrate profile that
permits hydrolysis of all cephalosporins, penicillins, and
aztreonam. These enzymes are most commonly produced by
Klebsiella spp. and Escherichia coli but may also occur in
other gram-negative bacteria, including Enterobacter,
Salmonella, Proteus, and Citrobacter  spp., Morganella
morganii,  Serratia marcescens, Shigella dysenteriae,
Pseudomonas aeruginosa, Burkholderia cepacia, and Capno-
cytophaga ochracea (3-9). Plasmid-mediated AmpC beta-
lactamases have arisen through the transfer of chromosomal
genes for the inducible AmpC beta-lactamase onto plasmids.
This transfer has resulted in plasmid-mediated AmpC beta-
lactamases in isolates of E. coli, Klebsiella pneumoniae,
Salmonella  spp., Citrobacter freundii, Enterobacter aero-
genes, and Proteus mirabilis (10-12). To date, all plasmid-
mediated AmpC beta-lactamases have similar substrate
profiles to the parental enzymes from which they appear to be
derived. With one exception (13), plasmid-mediated AmpCs
differ from chromosomal AmpCs in being uninducible. Both
ESBLs and plasmid-mediated AmpC beta-lactamases are
typically associated with broad multidrug resistance (usually
a consequence of genes for other antibiotic resistance
mechanisms residing on the same plasmids as the ESBL and
AmpC genes). A serious challenge facing clinical laboratories
is that clinically relevant ESBL-mediated resistance is not
always detectable in routine susceptibility tests.
Many clinical laboratories (as well as the wider medical
community) are not fully aware of the importance of ESBLs
and plasmid-mediated AmpCs and how to detect them;
laboratories may also lack the resources to curb the spread of
these resistance mechanisms (14-16). This lack of under-
standing or resources is responsible for a continuing failure to
respond appropriately to prevent the rapid worldwide
dissemination of pathogens possessing these beta-lactamases.
The consequence has been avoidable therapeutic failures
(sometimes fatal) in patients who received inappropriate
antibiotics (17-22) and outbreaks of multidrug-resistant, gram-
negative pathogens that required expensive control efforts (23).
I describe gaps in the capabilities of clinical laboratories
to accurately detect and report ESBLs and plasmid-mediated
AmpC beta-lactamases; discuss some of the technical
difficulties involved in designing tests to detect ESBLs in
organisms other than E. coli and Klebsiella spp.; correlate
laboratory problems with the recent emphasis on medical
cost-cutting at a time when bacterial pathogens are
increasing in complexity; and propose a way to improve
laboratory performance to meet the challenge of antibiotic
resistance.
Laboratory Testing for ESBLs and
Plasmid-Mediated AmpC beta-Lactamases
The National Committee for Clinical Laboratory
Standards (NCCLS) has issued recommendations for ESBL
screening and  confirmation for isolates of E. coli and
Klebsiella spp., and reporting confirmed organisms (24).
Compliance varies widely. Many laboratories have difficulty
detecting ESBL- or AmpC-mediated resistance and may be
unaware of the relevant NCCLS reporting guidelines (14). No
NCCLS recommendations exist for ESBL detection and
reporting for other organisms or for detecting plasmid-
mediated AmpC beta-lactamases.
In the United States, many laboratories await NCCLS
recommendations before attempting to detect new resistance
mechanisms. Thus, many clinical laboratories attempt to
detect ESBLs only in E. coli and Klebsiella spp. Some
researchers suggest that this is the correct approach and that
even discussion of such issues is unwarranted because it
causes confusion. However, other organisms possessing these
resistance mechanisms do cause infections, making this
stance unacceptable. Moreover, the laboratory is an early
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patients. An early warning system that allows time lags of 12
or more years before new types of resistant organisms are
detected is untenable. Twelve years is not an early warning,
and laboratories that operate in this manner cannot meet
their responsibility.
NCCLS and the Emergence of New Pathogens
Can the current deficiencies be rectified? Two issues
affect laboratories: the role of NCCLS and the speed with
which new types of pathogens are emerging. NCCLS’s task of
creating laboratory test recommendations is difficult and
often underappreciated. The committee has responsibilities
in the areas of regulation, standardization, and safety. It is
not NCCLS’s  role to be at the cutting edge of research, nor
would it be appropriate for it, or other similar bodies, to be
overly hasty and make decisions based on inadequate data. It
can take years to gather data about a new, relatively
uncommon, resistance mechanism. Time is also needed for
analysis and debate. Properly done, the process cannot be
rushed. The problem is that bacteria are evolving or adapting
faster than this process.
Today, many bacterial pathogens are more complex than
a decade or two ago. Thus, previously reliable susceptibility
tests may no longer be dependable. For example, there are not
only new resistance mechanisms, such as ESBLs, but also
isolates that produce multiple beta-lactamases. Such
organisms were not encountered often, if at all, when the
current NCCLS susceptibility test criteria were prepared. For
example, before the 1990s, K. pneumoniae isolates typically
produced a single beta-lactamase, SHV-1, or occasionally two
beta-lactamases (25-27). Today, K. pneumoniae isolates that
produce three to six beta-lactamases are commonplace in
some centers (28-34). Such changes necessitate new or modified
tests to provide accurate and clinically relevant susceptibility
reports. But instead of laboratory testing methods being
upgraded during the last decade, the emphasis has been on
cost-cutting and downsizing. Laboratories are under pressure
to use cheaper, abbreviated tests or merely to maintain the
technical status quo of a decade or more ago. In centers where
the newer, more complex pathogens occur, reliance on the
older tests leaves patients and institutions at risk.
A More Responsive Approach
One approach to overcoming such problems would be to
ensure that each laboratory has a staff member with the time,
interest, and expertise to provide leadership in antibiotic
testing and resistance. This person would read relevant
publications, network with other laboratories, and evaluate
potentially useful tests to detect new forms of resistance in the
vulnerable interim period before new NCCLS-recommended
tests become available. The person with this responsibility
should work closely with reference laboratories, such as those
of the Centers for Disease Control and Prevention or other
sites with expertise. This would help to ensure that, whenever
a new resistance mechanism is suspected, it would be
properly checked, and the reference laboratory could provide
feedback about whether the finding was “real.”
Unresolved Issues
The gaps in current laboratory knowledge and testing
have generated several unresolved issues. One is whether
positive, but unconfirmed, ESBL screens should be routinely
reported. This is a consequence of the NCCLS two-step
approach to ESBL detection. The first step is a screening for
reduced susceptibility to any of the recommended screening
agents (cefotaxime, ceftriaxone, ceftazidime, cefpodoxime, or
aztreonam). Confirmatory testing,  initiated only after a
positive screening result, is based on tests with combinations
of screening agents and the beta-lactamase inhibitor
clavulanate. This testing indirectly detects hydrolysis of a
screening agent by an ESBL by demonstrating potentiation of
the activity of a screening agent in the presence of the beta-
lactamase inhibitor. Confirmatory testing may require up to
one extra day to detect ESBLs. If the laboratory reports a
positive ESBL screening result to the physician and the
isolate subsequently proves to be ESBL negative, the report
could lead to unnecessary use of a carbapenem. Alternatively,
if the laboratory withholds the positive screening result and
the isolate is subsequently confirmed as ESBL positive,
appropriate therapy may have been delayed for a day.
Clearly, a reporting rule cannot cover all situations. Rather,
the need to report a positive screening result should be
determined on a case-by-case basis using common sense and
experience as guides, taking into account the patient’s status,
infection control considerations, and the likelihood of a
positive confirmatory test (based on prior experience with
isolates from the same patient population). Using a reliable,
rapid confirmatory test could minimize the time required for
the second-step test and lessen this reporting dilemma.
Another solution would be including ESBL confirmation
testing in the routine susceptibility test.
Another issue is which NCCLS screening agent should be
tested. Generally, the most reliable screening agent is the
most sensitive. Cefpodoxime is the most sensitive ESBL
screening agent for K. pneumoniae and E. coli, but a poor
screening agent for K. oxytoca (35). The superior sensitivity of
this agent can be accompanied by poor specificity in tests with
some ESBL-negative E. coli isolates. This is another problem
arising from the two-step approach to detecting ESBLs, which
could be avoided by including a confirmatory test (ideally
cefpodoxime plus clavulanate for K. pneumoniae and E. coli
isolates) in the routine susceptibility test (17,36).
How best to detect ESBLs in organisms other than
Klebsiella spp. or E. coli has not received much attention. The
inhibitor-based confirmatory test approach is the most
promising detection method (37). However, with isolates of
some species, clavulanate is an unreliable agent for this test.
The inhibitor-based approach is most reliable for isolates that
do not coproduce an inhibitor-resistant beta-lactamase, such
as AmpC. High-level expression of AmpC may prevent
recognition of an ESBL. This problem is more common in tests
with species or strains that produce a chromosomally encoded
inducible AmpC beta-lactamase (e.g., Enterobacter, Serratia,
Providencia, Aeromonas spp., M. morganii, C. freundii,
Hafnia alvei, and P. aeruginosa). With these organisms,
clavulanate may act as an inducer of high-level AmpC
production and increase the resistance of the isolate to other
screening drugs, producing a false-negative result in the
ESBL detection test (Table 1). Tazobactam and sulbactam are
much less likely to induce AmpC beta-lactamases and are
therefore preferable inhibitors for ESBL detection tests with
these organisms (37). Another possible solution is to include
cefepime as an ESBL screening agent (38). High-level AmpC
expression has minimal effect on the activity of cefepime,
making this drug a more reliable detection agent for ESBLs in
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A further concern with ESBL-producing organisms other
than  Klebsiella  and E. coli is reporting their antibiotic
susceptibilities. In Table 2, the beta-lactam MICs of an SHV-
3-producing  C. freundii isolate are within the NCCLS
susceptible range of  <8 µg/mL. If the isolate were Klebsiella or
E. coli, the NCCLS reporting rule would apply, and the isolate
would be reported as resistant to all penicillins, cephalospor-
ins, and aztreonam. However, there is no ESBL reporting rule
for other organisms; therefore, this organism would be
reported as susceptible to cefotaxime, ceftazidime, aztreonam,
and cefepime. This is inconsistent. Not only does this C.
freundii isolate produce an ESBL, it also produces a
chromosomal AmpC beta-lactamase that can hydrolyze the
cephalosporins and aztreonam. It therefore seems wrong to
report this organism as susceptible to these agents. Moreover,
when the organism was tested at a 100-fold higher-than-
standard inoculum, a dramatic inoculum effect occurred, with
large increases in the MICs of these agents, analogous to the
inoculum effect that occurs with ESBL-producing Klebsiella
spp. and E. coli (Creighton University, unpub. data). This
finding adds support for reporting all ESBL-producing
isolates, not just Klebsiella spp. and E. coli, as resistant to all
penicillins, cephalosporins, and aztreonam.
Detecting and reporting isolates producing plasmid-
mediated AmpC beta-lactamases are more difficult issues
than those associated with ESBLs. Detection is technically
difficult in organisms that also produce a chromosomal
AmpC, since proving that an AmpC is plasmid mediated, and
not the usual chromosomal enzyme, is necessary. This
determination is beyond the capabilities of most clinical
laboratories. However, Klebsiella spp. do not possess a
chromosomal AmpC. This makes them convenient indicator
organisms to screen when attempting to detect plasmid-
mediated AmpCs. Phenotypic tests for AmpC detection are
not well defined. Screening tests could be based on decreased
susceptibility to cephamycins. AmpC beta-lactamases are
resistant to all marketed beta-lactamase inhibitors.
Therefore, negative ESBL confirmatory tests based on these
inhibitors may provide indirect evidence of AmpC production,
or reduced outer membrane permeability. A positive three-
dimensional test result with cefoxitin demonstrates
hydrolysis of cefoxitin and differentiates between AmpC
production and reduced outer membrane permeability (39). If
an investigational AmpC beta-lactamase inhibitor were made
available for diagnostic testing, it could be used in
combination with a suitable cephem to confirm AmpC
production.
Susceptibility reporting may prove controversial for
isolates producing plasmid-mediated AmpC beta-lactamases.
Isolates that produce these enzymes can be susceptible in
vitro to cephalosporins and aztreonam (Table 3). If these
agents are used therapeutically for infections with such
organisms, determining if they pose a treatment failure risk
for patients is a priority.
Conclusions
Since clinical laboratories are first to encounter bacteria
with new forms of antibiotic resistance, they need appropriate
tools to recognize these bacteria, including trained staff with
sufficient time and equipment to follow up important
observations. Because bacterial pathogens are constantly
changing, training must be an ongoing process. As we have
learned from ESBLs, the methods and training that were
previously adequate may no longer suffice against the newer
types of pathogens. If laboratories continue to lag years
behind new bacterial developments, new pathogens will
spread, resulting in increasing problems and costs for
patients and institutions.
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